Immunotherapy Expert, Brad Loncar, Reveals Biotech Forecast for 2017
Our nation’s top biotech insiders are gathering at JP Morgan’s 35th annual Healthcare Conference in San Francisco next week.
I’ll be at the invitation-only event, which draws thousands of top fund mangers, analysts, investment bankers, and drug company CEOs together for an exclusive look at the most promising medical breakthroughs tee’d up for the coming year.
The press reports that “the stakes are higher than ever” for 2017, which makes me incredibly excited…
So this week, I sat down with biotech expert and creator of the Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR), Brad Loncar, to discuss the biggest trends and most exciting announcements to look out for at the conference.
Brad reveals the two branches of science with the greatest potential for medical innovation in 2017, and explains how he’ll be vetting managements’ confidence in all of latest drugs, technologies, and therapies.
It’s an episode you won’t want to miss. Click here to read a transcript.
